A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis

被引：0

作者：

Timothy J. Vreeland

Guy T. Clifton

Diane F. Hale

Robert C. Chick

Annelies T. Hickerson

Jessica L. Cindass

Alexandra M. Adams

Phillip M. Kemp Bohan

Robert H. I. Andtbacka

Adam C. Berger

James W. Jakub

Jeffrey J. Sussman

Alicia M. Terando

Thomas Wagner

George E. Peoples

Mark B. Faries

机构：

[1] Uniformed Services University of Health Sciences,Department of Surgery

[2] Brooke Army Medical Center,Department of Surgical Oncology

[3] University of Texas MD Anderson Cancer Center,Department of Surgical Oncology

[4] Brooke Army Medical Center,Department of Surgery

[5] Huntsman Cancer Institute,undefined

[6] Rutgers Cancer Institute of New Jersey,undefined

[7] Mayo Clinic,undefined

[8] University of Cincinnati Cancer Institute,undefined

[9] USC Norris Comprehensive Cancer Center,undefined

[10] Orbis Health Solutions,undefined

[11] Cancer Vaccine Development Program,undefined

[12] The Angeles Clinic,undefined

来源：

Annals of Surgical Oncology | 2021年 / 28卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

引用

页码：6126 / 6137

页数：11

共 50 条

[1] A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis
Vreeland, Timothy J.
Clifton, Guy T.
Hale, Diane F.
Chick, Robert C.
Hickerson, Annelies T.
Cindass, Jessica L.
Adams, Alexandra M.
Bohan, Phillip M. Kemp
Andtbacka, Robert H. I.
Berger, Adam C.
Jakub, James W.
Sussman, Jeffrey J.
Terando, Alicia M.
Wagner, Thomas
Peoples, George E.
Faries, Mark B.
ANNALS OF SURGICAL ONCOLOGY, 2021, 28 (11) : 6126 - 6137
[2] Interim analysis of a prospective, randomized, double blind, placebo controlled, phase IIb trial of the TLPLDC vaccine to prevent recurrence in resected stage III or IV melanoma patients
Myers, John William
Clifton, Guy T.
Hale, Diane F.
Brown, Tommy A.
Vreeland, Timothy J.
Andtbacka, Robert Hans Ingemar
Berger, Adam C.
Jakub, James W.
Sussman, Jeffrey J.
Terando, Alicia Maria
Faries, Mark B.
Peoples, George Earl
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[3] Subgroup Analysis of the Interim Results of a Prospective, Randomized, Double Blinded, Placebo Controlled, Phase IIb Trial of the Autologous TLPLDC Vaccine in Stage III/ IV ( Resected) Melanoma Patients to Prevent Recurrence
Myers, John W.
Clifton, Guy T.
Vreeland, Timothy J.
Brown, Tommy A.
Peace, Kaitlin
Greene, Julia M.
Jackson, Doreen O.
Hale, Diane F.
Peoples, George E., Jr.
Faries, Mark B.
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2018, 227 (04) : S249 - S249
[4] Trial redesign for the phase II/III DETECTION trial: circulating tumour DNA-guided therapy for stage IIB/C melanoma after surgical resection
Muinonen-Martin, Andy
Lee, Rebecca
Rothwell, Dominic
Jackson, Richard
Smith, Nigel
Wong, Stephen
Kelso, Noel
Hewitt, Chelsee
Mitchell, Jackie
Jones, Kate
Turajlic, Samra
Corrie, Pippa
Marais, Richard
Middleton, Mark
Dawson, Sarah-Jane
Sandhu, Shahneen
Dive, Caroline
Lorrigan, Paul
BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
[5] DETECTION phase II/III trial: Circulating tumor DNA-guided therapy for stage IIB/C melanoma after surgical resection.
Lee, Rebecca
Rothwell, Dominic G.
Jackson, Richard
Smith, Nigel
Wong, Stephen Q.
Kelso, Noel
Burghel, George
Hewitt, Chelsee
Clarke, Harry
Mitchell, Jackie
Jones, Kate
Muinonen-Martin, Andrew
Turajlic, Samra
Corrie, Philippa Gail
Marais, Richard
Middleton, Mark R.
Dawson, Sarah-Jane
Sandhu, Shahneen
Dive, Caroline
Lorigan, Paul
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[6] Assessment of Prognostic Circulating Tumor Cells in a Phase III Trial of Adjuvant Immunotherapy After Complete Resection of Stage IV Melanoma
Hoshimoto, Sojun
Faries, Mark B.
Morton, Donald L.
Shingai, Tatsushi
Kuo, Christine
Wang, He-jing
Elashoff, Robert
Mozzillo, Nicola
Kelley, Mark C.
Thompson, John F.
Lee, Jeffrey E.
Hoon, Dave S. B.
ANNALS OF SURGERY, 2012, 255 (02) : 357 - 362
[7] Adjuvant therapy with nivolumab (NIVO) versus ipilimumab (IPI) after complete resection of stage III/IV melanoma: A randomized, double-blind, phase 3 trial (CheckMate 238)
Weber, J.
Mandala, M.
Del Vecchio, M.
Gogas, H.
Arance, A. M.
Cowey, L. C.
Dalle, S.
Schenker, M.
Chiarion-Sileni, V.
Marquez-Rodas, I.
Grob, J-J.
Butler, M.
Middleton, M. R.
Maio, M.
Atkinson, V.
Queirolo, P.
de Pril, V.
Qureshi, A.
Larkin, J.
Ascierto, P. A.
ANNALS OF ONCOLOGY, 2017, 28
[8] Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Updated results from a phase 3 trial (CheckMate 238)
Weber, Jeffrey S.
Mandala, Mario
Del Vecchio, Michele
Gogas, Helen
Arance, Ana M.
Cowey, C. Lance
Dalle, Stephane
Schenker, Michael
Chiarion-Sileni, Vanna
Marquez-Rodas, Ivan
Grob, Jean-Jacques
Butler, Marcus
Middleton, Mark R.
Maio, Michele
Atkinson, Victoria
Dummer, Reinhard
de Pril, Veerle
Qureshi, Anila
Larkin, James
Ascierto, Paolo A.
BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 41 - 42
[9] A randomised trial evaluating bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma: an update
Biswas, S.
Wrigley, J.
East, C.
Hern, A.
Marshall, A.
Dunn, J.
Lorigan, P.
Middleton, M.
Corrie, P.
ECANCERMEDICALSCIENCE, 2008, 2
[10] Postoperative Adjuvant Therapy Versus Surgery Alone for Stage IIB-III Esophageal Squamous Cell Carcinoma: A Phase III Randomized Controlled Trial
Ni, Wenjie
Yu, Shufei
Xiao, Zefen
Zhou, Zongmei
Chen, Dongfu
Feng, Qinfu
Liang, Jun
Lv, Jima
Gao, Shugeng
Mao, Yousheng
Xue, Qi
Sun, Kelin
Liu, Xiangyang
Fang, Dekang
Li, Jian
Wang, Dali
Zhao, Jun
Gao, Yushun
ONCOLOGIST, 2021, 26 (12) : E2151 - E2160

← 1 2 3 4 5 →